IFIH1 and clinically amyopathic dermatomyositis: Current views regard anti-MDA5 level as a novel parameter for monitoring disease activity and a good predictor of rapidly progressing ILD (RP-ILD) and decreased survival in patients with DM or CADM (11, 14).